Aegerion Pharmaceuticals

Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. The Company's products include Juxtapid (lomitapide) and MYALEPT (metreleptin). Lomitapide is a small molecule microsomal triglyceride transfer protein, which is marketed under the brand name Juxtapid (lomitapide) capsules (Juxtapid) in the United States as an adjunct to a low-fat diet and other lipid-lowering treatments. Lomitapide was also approved in the European Union under the brand name LOJUXTA (lomitapide) hard capsules (LOJUXTA), as a treatment for homozygous familial hypercholesterolemia (HoFH) in adults. Metreleptin is a recombinant human leptin analog that exerts its function by binding to and activating the human leptin receptor and is available as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.
Company Growth (employees)
Type
Public
HQ
Cambridge, US
Founded
2005
Size (employees)
318 (est)
Aegerion Pharmaceuticals was founded in 2005 and is headquartered in Cambridge, US

Aegerion Pharmaceuticals Office Locations

Aegerion Pharmaceuticals has an office in Cambridge
Cambridge, US (HQ)
101 Main St

Aegerion Pharmaceuticals Data and Metrics

Aegerion Pharmaceuticals Financial Metrics

Aegerion Pharmaceuticals's revenue was reported to be $239.9 m in FY, 2015 which is a 51% increase from the previous period.
$, USD

Revenue (FY, 2015)

239.9 m

Revenue growth (FY, 2014 - FY, 2015), %

51%

Gross profit (FY, 2015)

187.6 m

Gross profit margin (FY, 2015), %

78%

Net income (FY, 2015)

(73.3 m)

EBIT (FY, 2015)

(45.2 m)

Market capitalization (29-Nov-2016)

58.2 m

Closing share price (29-Nov-2016)

1.9

Cash (31-Dec-2015)

64.5 m

EV

248.5 m
Aegerion Pharmaceuticals's current market capitalization is $58.2 m.
$, USDFY, 2013FY, 2014FY, 2015

Revenue

48.5 m158.4 m239.9 m

Revenue growth, %

226%51%

Cost of goods sold

5 m14.4 m52.3 m

Gross profit

43.5 m144 m187.6 m

Gross profit Margin, %

90%91%78%

Operating expense total

105.9 m170.7 m232.7 m

EBIT

(62.3 m)(26.7 m)(45.2 m)

EBIT margin, %

(128%)(17%)(19%)

Interest expense

453 k9.7 m27.6 m

Pre tax profit

63 m(38.5 m)(71.6 m)

Income tax expense

347 k899 k1.8 m

Net Income

(63.4 m)(39.4 m)(73.3 m)
$, USDFY, 2013FY, 2014FY, 2015

Cash

61 m375.9 m64.5 m

Accounts Receivable

7.6 m17.1 m13.6 m

Inventories

1.6 m9.5 m58.7 m

Current Assets

140.5 m407.4 m175.9 m

PP&E

1.7 m4.7 m4.9 m

Goodwill

9.6 m

Total Assets

142.3 m417.5 m434.2 m

Accounts Payable

4.1 m9.7 m10.8 m

Total Debt

7.6 m218.9 m254.8 m

Current Liabilities

24.8 m39.8 m86.9 m

Additional Paid-in Capital

369.1 m491 m519.2 m

Retained Earnings

(256.1 m)(295.5 m)(368.8 m)

Total Equity

113 m160.3 m115.5 m

Debt to Equity Ratio

0.1 x1.4 x2.2 x

Debt to Assets Ratio

0.1 x0.5 x0.6 x

Financial Leverage

1.3 x2.6 x3.8 x
$, USDFY, 2013FY, 2014FY, 2015

Net Income

(63.4 m)(39.4 m)(73.3 m)

Depreciation and Amortization

469 k1.2 m1.8 m

Accounts Receivable

(7.6 m)(9.6 m)(3.6 m)

Inventories

(1.6 m)(10.2 m)2.5 m

Accounts Payable

(1.1 m)5.5 m1.1 m

Cash From Operating Activities

(38.4 m)(2.1 m)16 m

Purchases of PP&E

(716 k)(3.9 m)(1.9 m)

Cash From Investing Activities

(22.8 m)60.2 m(326.9 m)

Cash From Financing Activities

85 m255.7 m(753 k)

Interest Paid

638 k402 k7.2 m

Income Taxes Paid

115 k1.1 m1.3 m
$, USDY, 2015

EV/EBIT

-5.5 x

EV/CFO

15.5 x

Revenue/Employee

813.2 k

Debt/Equity

2.2 x

Debt/Assets

0.6 x

Financial Leverage

3.8 x

Aegerion Pharmaceuticals Operating Metrics

FY, 2015

Patents (US)

7

Products

2

Aegerion Pharmaceuticals Revenue Breakdown

Aegerion Pharmaceuticals Online and Social Media Presence

Aegerion Pharmaceuticals Company Life and Culture

You may also be interested in